Dr. Scott Shandler is a CEO and principal investigator at Longevity Biotech and has been responsible for business development, fund raising and industry collaborations with other organizations. Previously, Dr. Shandler was a venture capitalist at BioAdvance, focused on investing in early-stage therapeutics companies. Earlier in his career, Dr. Shandler worked for Merck Research Labs, where he guided project portfolio prioritization efforts across the worldwide basic research neuroscience portfolio. Prior to Merck, he was a product manager for PolyMedix, an early-stage biotech company, and served as a subject matter expert in Accenture’s (ACN) Pharmaceutical and Medical Products group, advising leading pharmaceutical and biotechnology companies. Dr. Shandler received his PhD in biochemistry and molecular biophysics from the University of Pennsylvania and an MBA from The Wharton School. He also holds a BA in computer science from Brandeis University and a certificate of bioinformatics from Stanford University.